Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room

This study has been completed.
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
George Simpson, University of Southern California
ClinicalTrials.gov Identifier:
NCT00457366
First received: April 4, 2007
Last updated: January 29, 2014
Last verified: January 2014
  Purpose

In the Psychiatric Emergency Room, agitated patients are treated routinely with an I.M. Haloperidol "cocktail" (Haloperidol 5 mg, Lorazepam 2 mg, Cogentin 2 mg), which has proved to be an effective treatment. However, since it is an intramuscular injection, it is more complicated and perhaps less acceptable to patients as well as more likely to cause EPS (extrapyramidal symptoms). Of late in our emergency room, we started using high dose Quetiapine 300 mg PO to replace the "cocktail" for treating agitation. It has shown promising results.

This study is designed to compare the efficacy and safety of Quetiapine with the routine "cocktail for treatment of agitation.

The primary purpose of this study is to determine the efficacy and safety of Quetiapine by using high dose Quetiapine (300 mg) PO to treat agitated patients in the psychiatric emergency room.

The secondary purpose is to test the immediate effect on agitation caused by illicit drug abuse or the alcohol abuse.


Condition Intervention Phase
Agitation
Drug: Quetiapine
Drug: Cocktail (Haloperidol, Lorazepam, Cogentin)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Comparison Study of the Efficacy of a Rapid Titration of Quetiapine and Haloperidol in Agitated Adults in an Emergency Setting.

Resource links provided by NLM:


Further study details as provided by University of Southern California:

Primary Outcome Measures:
  • Decrease in the PANSS-EC two hours after administration of the medication. [ Time Frame: Two hours ] [ Designated as safety issue: No ]

Enrollment: 72
Study Start Date: May 2006
Study Completion Date: May 2009
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Quetiapine
Drug: Quetiapine
Quetiapine 300mg PO/Initial dose and repeat dose at 2 hours if deemed clinically necessary upto a maximum dose of Quetiapine 600mg PO QD
Active Comparator: 2
Cocktail (Haloperidol, Lorazepam, Cogentin)
Drug: Cocktail (Haloperidol, Lorazepam, Cogentin)
Haloperidol 5 mg im, Lorazepam 2 mg im, Cogentin 2 mg im; repeated at 2 hours as deemed clinically necessary

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. English or Spanish speaking patients
  2. Provision of written informed consent-English and Spanish
  3. Males and females age 18 to 60 years. Females who are pregnant by inspection should not be included.
  4. Provision at diagnosis meeting the Diagnostic and Statistical Manual of Mental Disorder, 4th edition (DSM-IV) criteria for Axis I documented who present in an agitated state. PANSS-EC score should be >15.
  5. Ability, in the treating physician's opinion, to co-operate with taking oral medication

Exclusion Criteria:

  1. Pregnant females who will thus receive routine care in the treating physician's opinion
  2. Unstable medical illness
  3. Withdrawal stage from any illicit drugs
  4. Psychosis that prohibits participation in trial
  5. Females of childbearing age where pregnancy cannot be confirmed or denied by screening
  6. Patients who required continued intervention or prolonged restraint
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00457366

Locations
United States, California
Los Angeles County Hospital
Los Angeles, California, United States, 90033
Sponsors and Collaborators
University of Southern California
AstraZeneca
Investigators
Principal Investigator: George M Simpson, MD USC+LAC Medical Center
  More Information

No publications provided

Responsible Party: George Simpson, Principal Investigator, University of Southern California
ClinicalTrials.gov Identifier: NCT00457366     History of Changes
Other Study ID Numbers: HS-05-00331
Study First Received: April 4, 2007
Last Updated: January 29, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Haloperidol
Haloperidol decanoate
Lorazepam
Quetiapine
Anti-Anxiety Agents
Anti-Dyskinesia Agents
Anticonvulsants
Antiemetics
Antipsychotic Agents
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dopamine Agents
Dopamine Antagonists
GABA Agents
GABA Modulators
Gastrointestinal Agents
Hypnotics and Sedatives
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents

ClinicalTrials.gov processed this record on November 19, 2014